David A. Siegel Arrowhead Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 38,800 shares of ARWR stock, worth $978,536. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,800
Previous 77,500
49.94%
Holding current value
$978,536
Previous $2.37 Million
53.23%
% of portfolio
0.0%
Previous 0.01%
Shares
19 transactions
Others Institutions Holding ARWR
# of Institutions
296Shares Held
88.5MCall Options Held
905KPut Options Held
387K-
Black Rock Inc. New York, NY15.3MShares$387 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.4MShares$313 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.56MShares$216 Million2.95% of portfolio
-
State Street Corp Boston, MA6.56MShares$165 Million0.01% of portfolio
-
Slate Path Capital LP New York, NY4.14MShares$104 Million2.38% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $2.67B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...